<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2958551-A1" country="EP" doc-number="2958551" kind="A1" date="20151230" family-id="51391882" file-reference-id="298230" date-produced="20180822" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="160454127" ucid="EP-2958551-A1"><document-id><country>EP</country><doc-number>2958551</doc-number><kind>A1</kind><date>20151230</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-14754426-A" is-representative="NO"><document-id mxw-id="PAPP193871222" load-source="docdb" format="epo"><country>EP</country><doc-number>14754426</doc-number><kind>A</kind><date>20140224</date><lang>EN</lang></document-id><document-id mxw-id="PAPP193871223" load-source="patent-office" format="original"><country>EP</country><doc-number>14754426.6</doc-number><date>20140224</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC162032885" ucid="US-201361768617-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>201361768617</doc-number><kind>P</kind><date>20130225</date></document-id></priority-claim><priority-claim mxw-id="PPC162028634" ucid="US-2014017935-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>2014017935</doc-number><kind>W</kind><date>20140224</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL-1890300303" load-source="ipcr">A61K   9/14        20060101AFI20160928BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1890300438" load-source="ipcr">A61P  37/04        20060101ALI20160928BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1984697863" load-source="docdb" scheme="CPC">A61K  47/44        20130101 LI20160108BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1984699210" load-source="docdb" scheme="CPC">A61K2039/55561     20130101 LA20160107BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1984699541" load-source="docdb" scheme="CPC">A61K  39/385       20130101 FI20160107BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1984701143" load-source="docdb" scheme="CPC">A61K2039/55516     20130101 LA20160107BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1984702275" load-source="docdb" scheme="CPC">A61K   9/1075      20130101 LI20160107BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1984703973" load-source="docdb" scheme="CPC">A61K2039/6018      20130101 LA20160107BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987774236" load-source="docdb" scheme="CPC">A61K2039/55555     20130101 LA20150113BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987790342" load-source="docdb" scheme="CPC">A61K   9/107       20130101 LI20141217BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987794492" load-source="docdb" scheme="CPC">A61K  47/186       20130101 LI20141217BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987799789" load-source="docdb" scheme="CPC">A61K  39/39        20130101 LI20150113BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT165553847" lang="DE" load-source="patent-office">PARTIKELFORMULIERUNGEN ZUR ABGABE VON TLR-AGONISTEN UND ANTIGENEN</invention-title><invention-title mxw-id="PT165553848" lang="EN" load-source="patent-office">PARTICLE FORMULATIONS FOR DELIVERY OF TLR AGONISTS AND ANTIGENS</invention-title><invention-title mxw-id="PT165553849" lang="FR" load-source="patent-office">FORMULATIONS PARTICULAIRES POUR L'ADMINISTRATION D'AGONISTES DU TLR ET D'ANTIGÈNES</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR1103327614" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>PARTICLE SCIENCES INC</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR1103309618" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>PARTICLE SCIENCES, INC.</last-name></addressbook></applicant><applicant mxw-id="PPAR1101646951" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Particle Sciences, Inc.</last-name><iid>101058545</iid><address><street>3894 Courtney Street Suite 180</street><city>Bethlehem, PA 18017</city><country>US</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR1103304048" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>MITCHNICK MARK</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103315431" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>MITCHNICK, MARK</last-name></addressbook></inventor><inventor mxw-id="PPAR1101647342" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>MITCHNICK, MARK</last-name><address><street>80 Three Mile Harbor Drive</street><city>East Hampton, NY 11937</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103329127" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>LOXLEY ANDREW</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103315280" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>LOXLEY, ANDREW</last-name></addressbook></inventor><inventor mxw-id="PPAR1101649610" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>LOXLEY, ANDREW</last-name><address><street>3984 Courtney Street, Suite 180,</street><city>Bethlehem, PA 18017</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103329663" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>GWOZDZ GARRY THOMAS</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103324691" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>GWOZDZ, GARRY, THOMAS</last-name></addressbook></inventor><inventor mxw-id="PPAR1101651624" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>GWOZDZ, GARRY, THOMAS</last-name><address><street>329 South Main Street</street><city>Nazareth, PA 18064</city><country>US</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR1101652903" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>O'Connell, Maura</last-name><suffix>et al</suffix><iid>100034058</iid><address><street>FRKelly 27 Clyde Road Ballsbridge</street><city>Dublin 4</city><country>IE</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="US-2014017935-W"><document-id><country>US</country><doc-number>2014017935</doc-number><kind>W</kind><date>20140224</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2014130921-A1"><document-id><country>WO</country><doc-number>2014130921</doc-number><kind>A1</kind><date>20140828</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS660649013" load-source="docdb">AL</country><country mxw-id="DS660652041" load-source="docdb">AT</country><country mxw-id="DS660649019" load-source="docdb">BE</country><country mxw-id="DS660765738" load-source="docdb">BG</country><country mxw-id="DS660731150" load-source="docdb">CH</country><country mxw-id="DS660796681" load-source="docdb">CY</country><country mxw-id="DS660796682" load-source="docdb">CZ</country><country mxw-id="DS660646369" load-source="docdb">DE</country><country mxw-id="DS660649020" load-source="docdb">DK</country><country mxw-id="DS660649021" load-source="docdb">EE</country><country mxw-id="DS660741852" load-source="docdb">ES</country><country mxw-id="DS660765743" load-source="docdb">FI</country><country mxw-id="DS660765744" load-source="docdb">FR</country><country mxw-id="DS660646370" load-source="docdb">GB</country><country mxw-id="DS660649022" load-source="docdb">GR</country><country mxw-id="DS660646375" load-source="docdb">HR</country><country mxw-id="DS660796683" load-source="docdb">HU</country><country mxw-id="DS660731155" load-source="docdb">IE</country><country mxw-id="DS660649027" load-source="docdb">IS</country><country mxw-id="DS660765745" load-source="docdb">IT</country><country mxw-id="DS660649028" load-source="docdb">LI</country><country mxw-id="DS660646376" load-source="docdb">LT</country><country mxw-id="DS660652042" load-source="docdb">LU</country><country mxw-id="DS660646377" load-source="docdb">LV</country><country mxw-id="DS660646378" load-source="docdb">MC</country><country mxw-id="DS660652055" load-source="docdb">MK</country><country mxw-id="DS660652056" load-source="docdb">MT</country><country mxw-id="DS660741853" load-source="docdb">NL</country><country mxw-id="DS660729637" load-source="docdb">NO</country><country mxw-id="DS660741854" load-source="docdb">PL</country><country mxw-id="DS660765746" load-source="docdb">PT</country><country mxw-id="DS660741867" load-source="docdb">RO</country><country mxw-id="DS660765783" load-source="docdb">RS</country><country mxw-id="DS660741868" load-source="docdb">SE</country><country mxw-id="DS660731156" load-source="docdb">SI</country><country mxw-id="DS660729638" load-source="docdb">SK</country><country mxw-id="DS660729643" load-source="docdb">SM</country><country mxw-id="DS660652057" load-source="docdb">TR</country></ep-contracting-states><ep-extended-states><ep-extended-state-data><country>BA</country></ep-extended-state-data><ep-extended-state-data><country>ME</country></ep-extended-state-data></ep-extended-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><abstract mxw-id="PA139071945" ref-ucid="WO-2014130921-A1" lang="EN" load-source="patent-office"><p num="0000">Compositions of one or more TLR agonists and one or more antigens adsorbed or attached to the same particles or to different particles are provided. Also provided are methods for producing and using these compositions.</p></abstract><abstract mxw-id="PA139539594" ref-ucid="WO-2014130921-A1" lang="EN" source="national office" load-source="docdb"><p>Compositions of one or more TLR agonists and one or more antigens adsorbed or attached to the same particles or to different particles are provided. Also provided are methods for producing and using these compositions.</p></abstract><abstract mxw-id="PA139071946" ref-ucid="WO-2014130921-A1" lang="FR" load-source="patent-office"><p num="0000">L'invention concerne des compositions comprenant un ou plusieurs agonistes du TLR et un ou plusieurs antigènes, adsorbés ou fixés à des particules identiques ou différentes. L'invention concerne aussi des procédés de production et d'utilisation de ces compositions.</p></abstract><abstract mxw-id="PA139539595" ref-ucid="WO-2014130921-A1" lang="FR" source="national office" load-source="docdb"><p>L'invention concerne des compositions comprenant un ou plusieurs agonistes du TLR et un ou plusieurs antigènes, adsorbés ou fixés à des particules identiques ou différentes. L'invention concerne aussi des procédés de production et d'utilisation de ces compositions.</p></abstract><description mxw-id="PDES78476308" ref-ucid="WO-2014130921-A1" lang="EN" load-source="patent-office"><!-- EPO <DP n="3"/>--><p id="p0001" num="0001"> Particle Formulations for Delivery of TLR Agonists and </p><p id="p0002" num="0002"> Antigens </p><p id="p0003" num="0003"> This patent application claims the benefit of priority from U.S. Provisional Application Serial No. 61/768,617 filed February 25, 2013, the contents of which are herein incorporated by reference in their entirety. </p><p id="p0004" num="0004">Field of the Invention </p><p id="p0005" num="0005"> The present invention relates to compositions </p><p id="p0006" num="0006">comprising one or more Toll-like Receptor (TLR) agonists and one or more antigens adsorbed or attached to the same particles or to different particles. In one embodiment, the present invention relates to a vaccine composition in which an antigen and a TLR agonist have been adsorbed or attached to the same particle or different particles. Such </p><p id="p0007" num="0007">compositions provide for improved vaccines with enhanced immunogenicity and/or reduced reactogenicity upon </p><p id="p0008" num="0008">administration . </p><p id="p0009" num="0009">Background of the Invention </p><p id="p0010" num="0010"> WO 2008/121926 describes pharmaceutical formulations containing particles comprised of hydrophobic organic material co-dissolved or co-dispersed with an active pharmaceutical ingredient. </p><p id="p0011" num="0011"> U.S. Patent 5,716,637 describes nanoemulsions of particles comprising a liquid core composed of a lipid which is solid or liquid at room temperature, which is stabilized by a phospholipid envelope. </p><p id="p0012" num="0012"> WO 2004/069227 describes a process for the preparation of a stable dispersion of solid particles, in an aqueous medium comprising by combining a pyrrole carboxamide 
<!-- EPO <DP n="4"/>-->
 compound, a water-miscible organic solvent and an inhibitor with an aqueous phase comprising water and a stabilizer. Bodmeier et al . (J. Microencapsulation 9(1) : 89-98 (1992)) describes forming microparticles by a melt dispersion technique, in which the drug-wax melt was emulsified into a heated aqueous phase followed by cooling to form the microparticles . </p><p id="p0013" num="0013">Summary of the Invention </p><p id="p0014" num="0014"> There exists a need to provide compositions and methods for delivering TLR agonist and antigen combinations wherein the ratio of TLR agonist and antigen can be altered to enhance antigen immunogenicity and/or reduce TLR agonist reactogenicity . </p><p id="p0015" num="0015"> An aspect of the present invention relates to </p><p id="p0016" num="0016">compositions and methods for producing and administering compositions comprising a ratio of TLR agonists and </p><p id="p0017" num="0017">antigens which enhance or increase tolerability of the vaccine while retaining the TLR activation activity. </p><p id="p0018" num="0018">Compositions and methods of present invention involve use of particles as a means for presenting antigens and TLR agonists in adjustable ratios which allow for optimization of immunogenicity to the antigen and/or reduction in reactogenicity to the TLR agonist. The use of particles in the compositions and methods of the present invention also permits non-proteinaceous antigens and existing purified vaccine antigen preparations to be combined with TLR agonists at ratios adjusted for optimization to optimize immunogenicity to the antigen and/or reduce in </p><p id="p0019" num="0019">reactogenicity to the TLR agonist. </p><p id="p0020" num="0020"> In one embodiment, the present invention relates to a composition comprising one or more TLR agonists and one or more antigens adsorbed or attached to the same particle. 
<!-- EPO <DP n="5"/>-->
 In one embodiment, the present invention relates to a composition comprising one or more TLR agonists adsorbed or attached to a first plurality of particles and one or more antigens adsorbed or attached to a second plurality of particles . </p><p id="p0021" num="0021"> Another aspect of the present invention relates to methods of manufacturing these particle compositions. </p><p id="p0022" num="0022"> Yet another aspect of the present invention relates to methods of using these particle compositions to invoke, increase and/or enhance an immune response to the antigen. </p><p id="p0023" num="0023">Brief Description of the Figures </p><p id="p0024" num="0024"> Figure 1 is a chart of the tunability of the surface charge of the particles of the invention by selection of particular emulsifiers or surfactants in the manufacture of the particles. Bars in the Figure labeled A through 0 stand for the following emulsifiers/surfactants : A=cationic silicone polymer; B= isostearylamidopropyldimethylamine gluconate; C=cetyltrimethylamino bromide </p><p id="p0025" num="0025"> (CTAB) ; D=cetylpyridinium bromide; E=dimethyldialkylammonium chloride; F=mannan; G=Brij 700; H=Brij 58; I=sodium heparin; J=gum acacia; K=disodium laurylsulfosuccinate ; L=sodium lauryl sulfate; M=sodium dodecyl benzene sulfonate; </p><p id="p0026" num="0026">N=disodium octylsulfosuccinate ; and O=triethanolammonium behenate . </p><p id="p0027" num="0027">Detailed Description of the Invention </p><p id="p0028" num="0028"> The present invention provides particle compositions where one or more TLR agonists and one or more antigen are attached or adsorbed to the same particle or different particles in ratios adjustable to optimize immunogenicity to the antigen and/or reduce reactogenicity to the TLR agonist. Accordingly, particle compositions of the present invention 
<!-- EPO <DP n="6"/>-->
 allow for TLR agonist to antigen ratios that are adjustable and differ from the 1:1 ratios required by fusion of a TLR agonist with an antigen as in the previous art. In one embodiment of the present invention, the compositions comprise particles where the ratio of the one or more TLR agonists to one or more antigens is less than 1:1 or more than 1:1 on either a weight to weight basis or molecule to molecules basis. In another embodiment of the present invention, the composition comprises one or more TLR agonists and one or more antigens located on different pluralities of particles and the ratio of TLR agonist to antigen is different than 1:1 as in the case of fusions of TLR agonist with antigen. The particle compositions of the present invention include particles where the ratio of the TLR agonist to antigen is less than 1:1 or more than 1:1 on either a weight to weight basis or molecule to molecules basis . </p><p id="p0029" num="0029"> By Toll-like Receptors or TLRs as used herein, it is meant to refer to the family of receptor proteins that are homologous to the Drosophila melanogaster Toll protein. TLRs are Type I transmembrane signaling receptor proteins characterized by an extracellular leucine-rich repeat domain and an intracellular domain homologous to an interleukin 1 receptor. TLRs include TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLRll and TLR12. </p><p id="p0030" num="0030"> By "TLR agonist" for purposes of the present invention, it is meant an agent that has an affinity for and stimulates physiologic activity of a TLR normally stimulated by naturally occurring substances. For TLRl, examples of agonists include, but are not limited to, triacyl </p><p id="p0031" num="0031">lipopeptides , glycolipids, lipopeptides and lipoproteins. For TLR2, examples of agonists include, but are not limited to, lipoteichoic acid, HSP70, and zymosan. For TLR3, 
<!-- EPO <DP n="7"/>-->
examples of agonists include, but are not limited to, double-stranded RNA, poly I:C lipopolysaccharide, fibrinogen and various heat shock proteins. For TLR4, examples of agonists include, but are not limited to, fragments of heparin sulfate and hyaluronic acid, nickel and various opioids. For TLR5, examples of agonists include, but are not limited to, flagellin. For TLR6, examples of agonists include, but are not limited to, various diacyl lipopeptides and imidazoquinoline . For TLR7, examples of agonists include, but are not limited to, guanosine analogues such as loxoribine, bropirimine and single-stranded RNA. For TLR8, examples of agonists include, but are not limited to, small synthetic compounds and single-stranded RNA. For TLR9, examples of agonists include, but are not limited to, unmethylated CpG oligodeoxynucleotide DNA. For TLR10, examples of agonists include, but are not limited to, profilin. In one embodiment of the present invention, the TLR agonist has an affinity for and stimulates physiologic activity of either TLRl, TLR2 , TLR3, TLR4, TLR6, TLR7 , TLR8, TLR9, TLR10, TLRll or TLR12. In one embodiment of the present invention, the TLR agonist has an affinity for and stimulates physiologic activity of TLR5. </p><p id="p0032" num="0032"> Any antigen that will provoke an immune response in a human can be used in the particle compositions of the present invention in combination with a TLR agonist. By antigen, it is meant to include, but is not limited to protein, peptide, carbohydrate, glycoprotein, lipopeptide, and subunit antigens. Examples of antigens used in the compositions of the present invention include, but are not limited to, viral antigens such as influenza viral antigens (e.g. hemagglutinin (HA) protein from influenza A, B and/or C where the influenza viral hemagglutinin protein may be at least one member selected from the group consisting of Hi, 
<!-- EPO <DP n="8"/>-->
 H2, H3, H5, H7 and H9, matrix 2 (M2) protein, neuraminidase), respiratory synctial virus (RSV) antigens (e.g. fusion protein, attachment glycoprotein), </p><p id="p0033" num="0033">papillomaviral (e.g. human papilloma virus (HPV) , such as an E6 protein, E7 protein, Ll protein and L2 protein) , Herpes Simplex, rabies virus and flavivirus viral antigens (e.g. Dengue viral antigens, West Nile viral antigens), hepatitis viral antigens including antigens from HBV and HC . Antigens used in the compositions of the present invention also include, but are not limited to, bacterial antigens </p><p id="p0034" num="0034">including those from Streptococcus pneumonia, Haemophilus influenza , Staphylococcus aureus, Clostridium difficile and enteric gram-negative pathogens including Escherichia , Salmonella , Shigella , Yersinia , Klebsiella , Pseudomonas, Enterobacter, Serratia, Proteus. Antigens used in the compositions of the present invention also include, but are not limited to fungal antigens including those from Candida spp. , Aspergillus spp., Crytococcus neoformans, Coccidiodes spp. , Histoplasma capsulatum, Pneumocystis carinii, </p><p id="p0035" num="0035">Paracoccidiodes brasiliensis, Plasmodium falciparum, </p><p id="p0036" num="0036"> Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae . Antigens for HPV vaccines would include El, E2, E3, E4, E5, E6, E7, and the N terminus of HPVL2 alone or in combination. Antigens for RSV vaccines include, but are not limited to, RSV F or G proteins, alone or in combination. Antigens for malaria vaccines include, but are not limited to, the CSPl protein, other pre-erythrocytic stage antigens and </p><p id="p0037" num="0037">transmission-blocking antigens (such as, Pfs25, Pfs48 and homologues) alone or in combination. Antigens used in the present invention also include tumor antigens and/or tumor associated antigens such as, but not limited to, PSA, CEA, Mart-1, gplOO, TRP-1, MAGE, NY-ESO-1, PAP, Mucin-1 and PSMA. Embodiments of the present invention also include particles 
<!-- EPO <DP n="9"/>-->
 with a TLR agonist and dengue antigen (s) adsorbed thereto. The Dengue disease is caused by four mosquito-borne, serologically related flaviviruses know as DEN 1 (also referred herein as Den 1), DEN 2 (Den-2), DEN 3 (Den 3) or DEN 4 (Den 4) . The compositions of the invention include antigens sequences such as those sequences disclosed in WO 2009/128949 ( PCT/US2009/002427 ) , Izquierdo et al . , 2008 - 814669, Mota et al., 2005, Khanam et al . , 2006, Pattnaik et al., 2007, Tripathi et al . , 2008; A. Zulueta, et al . , Virus Research 121 (2006) 65-73 herein incorporated by reference. In one embodiment the antigen is TlBT, a polyoxime, </p><p id="p0038" num="0038">constructed by chemoselective ligation, via oxime bonds, of a tetrabranched core with a peptide module containing B cell epitopes and a universal T cell epitope of the Plasmodium falciparum circumsporozoite protein. </p><p id="p0039" num="0039"> Various particles can be used in the particle </p><p id="p0040" num="0040">compositions of the present invention. </p><p id="p0041" num="0041"> In one embodiment, lipids are used to make the </p><p id="p0042" num="0042">particles. Examples of lipids which can be used include, but are not limited to, carnauba wax, bees wax, behenyl alcohol (docosanol) , cetyl alcohol, microcrystalline triglycerides such as dynasan 118 (glyceryl tristearate) and polyethylene wax. In one embodiment, the lipid is carnauba wax including a carnauba comprising aliphatic esters, diesters of 4-hydroxycinnamic acid, ω-hydroxycarboxylic acids and fatty acid alcohols . </p><p id="p0043" num="0043"> However, as will be understood by the skilled artisan upon reading this disclosure, particles may be comprised of non-lipids as well. </p><p id="p0044" num="0044"> In one embodiment, the particle compositions further comprise a surfactant. Surfactants that may be used in the particle compositions include cationic, anionic and non- ionic surfactants. Examples of surfactants include, but are 
<!-- EPO <DP n="10"/>-->
not limited to, cetyl triammonium bromide (CTAB) , N-[l-(2,3- Dioleoyloxy) ] -N, N, -trimethylammonium propane methylsulfate DOTAP, cetylpyridinium bromide (CPB) , polysorbate </p><p id="p0045" num="0045">surfactants such as Tween 20, Tween 80 (polyoxyethylene sorbitan monoloaurate) , polyethylene stearyl ether such as Brij 70, sodium stearate, sodium myristate, sodium dodecyl sulfate, Dioctyl sodium sulfosuccxnate such as AOT and combinations thereof. The surfactant may present in a level from about 0.01% to about 10%, or from about 0.05% to about 5% or from about 0.1% to about 2% or from about 0.5% to about 2% or from about 1.0% to about 2.0%. </p><p id="p0046" num="0046"> In one embodiment, the surface charge on the particle is altered to optimize attachment of the TLR agonist and/or antigen by attaching charged moieties or adjusting the type of surfactant and/or matrix used in the production of the particles . </p><p id="p0047" num="0047"> Figure 1 demonstrates how the surface charge of the particles can be altered based on the selection of the surfactant . </p><p id="p0048" num="0048"> Particle size is preferably less than Ιμπι with the particles ranging in size between about lOnm to lOOOnm or between about 20nm to about 900 nm or from about 30nm to abut 800nm or from about 0nm to about 700nm or from about 50nm to about 650nm or from about lOOnm to about 750nm or from about 200nm to about 750nm or from about 300nm to about 750 nm or from about 300nm to about 650nm or from about 400nm to about 750nm or from about 00nm to about 660nm or from about 500nm to about 750nm or from about 500nm to about 650nm. Particle shape may be, but is not limited to spheres, prolate and oblate spheroids, cylindrical, and irregular shapes. </p><p id="p0049" num="0049"> Compositions of the present invention may further comprise a targeting moiety such as, but not limited to an 
<!-- EPO <DP n="11"/>-->
 antibody or Fabs . Such targeting moieties are also attached to the particle. </p><p id="p0050" num="0050"> The invention further relates to methods of </p><p id="p0051" num="0051">manufacturing these particle compositions. </p><p id="p0052" num="0052"> In one embodiment, the method comprises a melt- emulsification-chill process in which a hot aqueous </p><p id="p0053" num="0053">surfactant solution is added to a melted lipid. The mixture is then sonicated and cooled to produce solidified lipid particles. In one embodiment, the hot aqueous surfactant solution comprises a cationic surfactant solution which is added to melted wax comprised of aliphatic esters, diesters of 4-hydroxycinnamic acid, ω-hydroxycarboxylic acids and fatty acid alcohols. A nonlimiting example of a melted wax is Yellow Carnauba wax (YC) comprised of 40% aliphatic esters, 21% diesters of 4-hydroxycinnamic acid, 13% ω~ hydroxycarboxylic acids and 12% fatty acid alcohols. This process produces a solidified lipid particle having </p><p id="p0054" num="0054">surfactant molecules oriented such that their heads are on the outer surface of the particle while the hydrophilic tails are toward the interior of the particle. </p><p id="p0055" num="0055"> The present invention further relates to methods of making immunologic formulations comprising preparing a hot aqueous surfactant solution, adding the hot surfactant to a molten lipid, adding this mixture to an aqueous phase, cooling the mixture and adding TLR agonist (s) and/or antigen (s) . </p><p id="p0056" num="0056"> In the particle compositions of the present invention, the antigen (s) and/or TLR agonist (s) are absorbed or attached to the particles by non-covalent interactions such as hydrophilic or electrostatic interactions . </p><p id="p0057" num="0057"> The particle compositions of the invention provide immunologic compositions that are more potent than the antigen alone. The particle compositions of the invention 
<!-- EPO <DP n="12"/>-->
 may also provide immunologic compositions in which the TLR agonist provokes a TLR mediated response, but in which the reactogenicity of the TLR agonist is reduced compared to the TLR agonist in solution when administered. </p><p id="p0058" num="0058"> The compositions and methods of the present invention employ any TLR agonist in combination with an antigen. In one embodiment, the TLR agonist is a TLR-5 agonist. In this embodiment, a preferred TLR-5 agonist is flagellin and in particular the type 2 flagellin of Salmonella typhimurium, however any of a variety of flagellins capable of binding and triggering TLR-5 may be used for this invention </p><p id="p0059" num="0059">including engineered flagellins as described in WO </p><p id="p0060" num="0060">2009/128950 herein incorporated by reference. </p><p id="p0061" num="0061"> Unlike the prior art methods of combining a TLR agonist with an antigen which required a one-to-one correspondence of agonist to antigen, the present invention relates to compositions that do not require a one-to-one correspondence of the agonist to antigen. In the present compositions, the TLR agonist may be present in lesser amount than the antigen when both the agonist and antigen are coupled to the particle. For example the ratio of TLR agonist to antigen may be less than about 1:2 or 1:3 or 1:4 or 1:5 or 1:6 or 1:7 or 1:8 or 1:9 or 1:10 or from about 1:20 or 1:30 or 1:50 or 1:100 or 1:250 or 1:500 or 1:1000 or 1:10,000 as measured by the number of molecules of TLR agonist and the number of molecules of antigen. Also the ratio of TLR agonist to antigen may be less than about 1:2 or 1:3 or 1:4 or 1:5 or 1:6 or 1:7 or 1:8 or 1:9 or 1:10 or from about 1:20 or 1:30 or 1:50 or 1:100 or 1:250 or 1:500 or 1:1000 or 1:10,000 as measured by a weight to weight comparison of TLR agonist to the antigen. Conversely, the compositions of the present invention include those compositions where the antigen is present in an amount less than the TLR agonist. For example 
<!-- EPO <DP n="13"/>-->
 the ratio of antigen to the TLR agonist may be less than about 1:2 or 1:3 or 1:4 or 1:5 or 1:6 or 1:7 or 1:8 or 1:9 or 1:10 or from about 1:20 or 1:30 or 1:50 or 1:100 or 1:250 or 1:500 or 1:1000 or 1:10,000 as measured by the number of molecules of TLR agonist and the number of molecules of antigen. Also the ratio of antigen to TLR agonist may be less than about 1:2 or 1:3 or 1:4 or 1:5 or 1:6 or 1:7 or 1:8 or 1:9 or 1:10 or from about 1:20 or 1:30 or 1:50 or 1:100 or 1:250 or 1:500 or 1:1000 or 1:10,000 as measured by a weight to weight comparison of TLR agonist to the antigen. The compositions of the present invention may comprise more than one type of antigen whether the antigen is from the same organism or a different organism. The compositions of the present invention may comprise more than one type of TLR agonist such as more than one type of flagellin from the same organism or from different organisms. </p><p id="p0062" num="0062"> The dose of TLR agonist and antigen may be selected to optimize the immunogenic response while attempting to keep reactogenicity low. At least one dose selected from the group consisting of a O.l g, 0.5 g, l]ig dose, 2 g dose, 3μg dose, 4 g dose, 5μg dose, 6μg dose, 7μg dose, 8pg dose, 9μg dose, 10 g dose, 15 g dose, 20 g dose, 25μg dose and a 30μg dose may be sufficient to induce an immune response in humans . The dose of the TLR agonist and antigen may be administered to the human within a range of doses including from about 0. ^g to about 500 g, ^g to about 100μg, ^g to about 50]ig, from about ^g to about 30 g, from about l g to about 25μg, from about l\ig to about 20μg, from about ^g to about 15 g, from about l g to about 10μg, from about 2 g to about 50μg, 2μg to about 30μg, from about 2μg to about 20μg, from about 2μg to about 10μg, from about 2μg to about 8μg, from about 3μg to about 50μg, 3μg to about 30μg, from about 3μg to about 20μg, from about 3μg to about 10μg, from about 
<!-- EPO <DP n="14"/>-->
 3pg to about 8 g, from about 3 g to about 5μg, from about g to about 50μg, 4μg to about 3C^g, from about 4 g to about 20 g, from about 4μg to about 10 g, from about 4μg to about 8μg, from about 5μg to about 5C^g, 5μg to about 30μ9, from about 5μg to about 2C^g, from about 5μg to about 10μg, from about 5μg to about 9μg, and from about 5μg to about 8μ<sub>5</sub>. </p><p id="p0063" num="0063"> With respect to compositions comprising a TLR agonist and antigen, the dosage refers to the amount of total protein present in the vaccine given to the human wherein some of the protein quantity relates to the antigen and some of the protein quantity relates to the TLR agonist. </p><p id="p0064" num="0064">The immunogenic compositions for use according to the present invention may be delivered as a standard 0.01 - 2.0 ml injectable dose and contain from about 0. ^g to about 50μg of antigen. In a preferred embodiment of the </p><p id="p0065" num="0065">immunogenic compositions for use according to the present invention is a 0.1 ml injectable dose and contains about ^g of antigen, 1.4]ig of carnauba wax and 0.14μg of surfactant. The vaccine volume may be between 0.05 and 1.0 ml or between about 0.05 and 0.5ml or about 0.10 to about 0.25 ml. A vaccine dose according to the present invention may be provided in a smaller volume than conventional dosing. Low volume doses according to the present invention are suitably below 0.5ml, typically below 0.3ml and usually not less than 0.01 ml. </p><p id="p0066" num="0066"> Thus, the present invention provides compositions and methods for optimizing the antigenicity (i.e. increasing the antigenicity) and/or the reactogenicity (i.e. decreasing the reactogenicity) of TLR agonist/antigen combinations either as composed on single particles or as composed on separate particles, including antigen/TLR agonist combinations that have been poorly immunogenic and/or highly reactogenic. The 
<!-- EPO <DP n="15"/>-->
 immunogenic particle compositions of the present invention comprising one or more TLR agonists and one or more antigens may be more immunogenic than the combination of TLR agonist and antigen as a fusion protein. For example, the </p><p id="p0067" num="0067">immunogenxcity of the antigen as measured by the antibody response to the antigen may be greater for the particle compositions of the present invention than the antigen alone in solution or as a TLR agonist-antigen fusion by greater than about 10% or greater than about 20% or greater than about 30% or greater than about 40% or greater than about 50% or greater than about 60% or greater than about 70% or greater than about 80% or greater than about 90% or greater than about 100% or greater than about 200% or greater than about 500% or greater than about 1000%. The immunogenic particle compositions comprising one or more TLR agonists and one or more antigens may be less reactogenic than the combination of TLR agonist and antigen as a fusion protein. For example, the reactogenicity to the TLR agonist as measured by the antibody response to the TLR agonist may be less for the particle compositions of the present invention than the antigen alone in solution or as a TLR agonist- antigen fusion by less than about 10% or less than about 20% or less than about 30% or less than about 40% or less than about 50% or less than about 60% or less than about 70% or less than about 80% or less than about 90% or less than about 100% or less than about 200% or less than about 500% or less than about 1000%. While the TLR agonist is less reactogenic in the compositions of the present invention, the particle compositions of the present invention still maintain the ability to trigger a TLR agonist response. </p><p id="p0068" num="0068"> Accordingly, the compositions and methods of the present invention are useful in production of vaccine formulations to invoke an immune response in a human. 
<!-- EPO <DP n="16"/>-->
 Further, the compositions of the present invention are useful in increasing antibody response to an antigen, even a poorly antigenic antigen, in an animal in order to generate therapeutic and or diagnostic antibodies to be extracted and purified. </p><p id="p0069" num="0069"> Ranges may be expressed herein as from about one particular value, and/or to about another particular value. When such a range is expressed, another aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as </p><p id="p0070" num="0070">approximations, by use of the antecedent about, it will be understood that the particular value forms another aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint . Where ranges are given herein, the endpoints are included. </p><p id="p0071" num="0071">Furthermore, it is to be understood that unless otherwise indicated or otherwise evident from the context and </p><p id="p0072" num="0072">understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or sub range within the stated ranges in different </p><p id="p0073" num="0073">embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise. </p><p id="p0074" num="0074"> Within this disclosure, any indication that a feature is optional is intended provide adequate support (e.g., under 35 D.S.C. 112 or Art. 83 and 84 of EPC) for claims that include closed or exclusive or negative language with reference to the optional feature. Exclusive language specifically excludes the particular recited feature from including any additional subject matter. For example, if it is indicated that A can be drug X, such language is intended to provide support for a claim that explicitly specifies 
<!-- EPO <DP n="17"/>-->
 that A consists of X alone, or that A does not include any other drugs besides X. "Negative" language explicitly excludes the optional feature itself from the scope of the claims. For example, if it is indicated that element A can include X, such language is intended to provide support for a claim that explicitly specifies that A does not include X. Non-limiting examples of exclusive or negative terms include "only," "solely," "consisting of," "consisting essentially of," "alone," "without", "in the absence of (e.g., other items of the same type, structure and/or function)" </p><p id="p0075" num="0075"> "excluding," "not including", "not", "cannot," or any combination and/or variation of such language. </p><p id="p0076" num="0076"> Similarly, referents such as "a," "an," "said," or "the," are intended to support both single and/or plural </p><p id="p0077" num="0077">occurrences unless the context indicates otherwise. For example "a dog" is intended to include support for one dog, no more than one dog, at least one dog, a plurality of dogs, etc. Non-limiting examples of qualifying terms that indicate singularity include "a single", "one," "alone", "only one," "not more than one", etc. Non-limiting examples of qualifying terms that indicate (potential or actual) plurality include "at least one, " "one or more, " "more than one," "two or more," "a multiplicity," "a plurality," "any combination of, " "any permutation of, " "any one or more of, " etc. Claims or descriptions that include "or" between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. </p><p id="p0078" num="0078"> All publications and patents cited in this </p><p id="p0079" num="0079">specification are herein incorporated by reference as if each individual publication or patent were specifically and 
<!-- EPO <DP n="18"/>-->
 individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. </p><p id="p0080" num="0080"> While this invention has been particularly shown and described with references to example embodiments thereof, it will be understood by those skilled in the art that the various changes in form and details may be made therein without departing from the scope of the invention </p><p id="p0081" num="0081">encompassed by the appended claims. </p><p id="p0082" num="0082">EXAMPLES </p><p id="p0083" num="0083"> Example 1 : Manufacture of Particle Formulations </p><p id="p0084" num="0084"> Selection of Antigen and TLR agonist </p><p id="p0085" num="0085"> Antigen A is selected from antigens for any of the infectious disease listed in Table 1 (also see en.wikipedia with the extension . org/wiki/List_of_infectious_diseases of the world wide web) . </p><p id="p0086" num="0086">Table 1 : List of infectious diseases in Humans </p><p id="p0087" num="0087">DISEASE SOURCE OF DISEASE </p><p id="p0088" num="0088"> Acinetobacter infections Acinetobacter baumannii </p><p id="p0089" num="0089"> Actinomyces israelii, Actinomyces</p><p id="p0090" num="0090">Actinomycosis gerencseriae and </p><p id="p0091" num="0091"> Propionibacterium propionicus</p><p id="p0092" num="0092">African sleeping sickness </p><p id="p0093" num="0093"> Trypanosoma brucei </p><p id="p0094" num="0094"> (African trypanosomiasis) </p><p id="p0095" num="0095"> AIDS (Acquired </p><p id="p0096" num="0096"> HIV (Human immunodeficiency immunodeficiency </p><p id="p0097" num="0097"> virus ) </p><p id="p0098" num="0098">syndrome) </p><p id="p0099" num="0099"> Amebiasis Entamoeba histolyti </p><p id="p0100" num="0100"> Anaplasmosis Anaplasma genus </p><p id="p0101" num="0101"> Anthrax Bacillus anthracis </p><p id="p0102" num="0102"> Arcanobacterium </p><p id="p0103" num="0103"> Arcanobacterium haemolyticum haemolyticum infection </p><p id="p0104" num="0104"> Argentine hemorrhagic </p><p id="p0105" num="0105"> Junin virus </p><p id="p0106" num="0106">fever 
<!-- EPO <DP n="19"/>-->
DISEASE SOURCE OF DISEASE </p><p id="p0107" num="0107"> Ascariasis Ascaris lumbricoides </p><p id="p0108" num="0108">Aspergillosis Aspergillus genus </p><p id="p0109" num="0109">Astrovirus infection Astroviridae family </p><p id="p0110" num="0110">Babesiosis Babesia genus </p><p id="p0111" num="0111"> Bacillus cereus infection Bacillus cereus </p><p id="p0112" num="0112"> Bacterial pneumonia multiple bacteria </p><p id="p0113" num="0113"> Bacterial vaginosis (BV) multiple bacteria </p><p id="p0114" num="0114"> Bacteroides infection Bacteroides genus </p><p id="p0115" num="0115"> Balantidiasis Balantidium coli </p><p id="p0116" num="0116"> Baylisascaris infection Baylisascaris genus </p><p id="p0117" num="0117"> BK virus infection BK virus </p><p id="p0118" num="0118"> Black piedra Piedraia hortae </p><p id="p0119" num="0119"> Blastocystis hominis </p><p id="p0120" num="0120"> Blastocystis hominis </p><p id="p0121" num="0121">infection </p><p id="p0122" num="0122"> Blastomycosis Blastomyces dermatitidis </p><p id="p0123" num="0123"> Bolivian hemorrhagic </p><p id="p0124" num="0124"> Machupo virus </p><p id="p0125" num="0125">fever </p><p id="p0126" num="0126"> Borrelia infection Borrelia genus </p><p id="p0127" num="0127"> Clostridium botulinum; Note: </p><p id="p0128" num="0128"> Botulism (and Infant Botulism is not an infection by botulism) Clostridium botulinum but caused by the intake of botulinum toxin.</p><p id="p0129" num="0129">Brazilian hemorrhagic </p><p id="p0130" num="0130"> Sabia </p><p id="p0131" num="0131">fever </p><p id="p0132" num="0132"> Brucellosis Brucella genus </p><p id="p0133" num="0133"> usually Burkholderia cepacia and</p><p id="p0134" num="0134">Burkholderia infection </p><p id="p0135" num="0135"> other Burkholderia species </p><p id="p0136" num="0136"> Buruli ulcer Mycobacterium ulcerans </p><p id="p0137" num="0137"> Calicivirus infection </p><p id="p0138" num="0138"> Caliciviridae family </p><p id="p0139" num="0139">(Norovirus and Sapovirus) </p><p id="p0140" num="0140"> Camp lobacteriosis Campylobacter genus </p><p id="p0141" num="0141">Candidiasis (Moniliasis; usually Candida albicans and Thrush) other Candida species </p><p id="p0142" num="0142"> Cat-scratch disease Bartonella henselae </p><p id="p0143" num="0143"> usually Group A Streptococcus and Cellulitis </p><p id="p0144" num="0144"> Staphylococcus </p><p id="p0145" num="0145"> Chagas Disease (American </p><p id="p0146" num="0146"> Trypanosoma cruzi </p><p id="p0147" num="0147">trypanosomiasis ) </p><p id="p0148" num="0148"> Chancroid Haemophilus ducreyi </p><p id="p0149" num="0149"> Chickenpox Varicella zoster virus (VZV)</p><p id="p0150" num="0150">Chlamydia Chlamydia trachomatis </p><p id="p0151" num="0151"> Chlamydophila pneumoniae Chlamydophila pneumoniae 
<!-- EPO <DP n="20"/>-->
 SOURCE OF DISEASE </p><p id="p0152" num="0152">infection </p><p id="p0153" num="0153">Cholera Vibrio cholerae </p><p id="p0154" num="0154"> Chromoblastomycosis usually Fonsecaea pedrosoi</p><p id="p0155" num="0155">Clonorchiasis Clonorchis sinensis </p><p id="p0156" num="0156"> Clostridium difficile </p><p id="p0157" num="0157"> Clostridium difficile </p><p id="p0158" num="0158">infection </p><p id="p0159" num="0159"> Coccidioides immitis and </p><p id="p0160" num="0160"> Coccidioidomycosis </p><p id="p0161" num="0161"> Coccidioides posadasii </p><p id="p0162" num="0162"> Colorado tick fever (CTF) Colorado tick fever virus (CTFV)</p><p id="p0163" num="0163">Common cold (Acute viral </p><p id="p0164" num="0164"> usually rhinoviruses and rhinopharyngitis; Acute </p><p id="p0165" num="0165"> coronaviruses . </p><p id="p0166" num="0166">coryza) </p><p id="p0167" num="0167"> Creutzfeldt-Jakob disease </p><p id="p0168" num="0168"> CJD prion </p><p id="p0169" num="0169"> (CJD) </p><p id="p0170" num="0170"> Crimean-Congo hemorrhagic Crimean-Congo hemorrhagic fever fever (CCHF) virus </p><p id="p0171" num="0171"> Cryptococcosis Cryptococcus neoformans </p><p id="p0172" num="0172"> Cryptosporidiosis Cryptosporidium genus </p><p id="p0173" num="0173"> Cutaneous larva migrans usually Ancylostoma braziliense; (CLM) multiple other parasites </p><p id="p0174" num="0174"> Cyclosporiasis Cyclospora cayetanensis </p><p id="p0175" num="0175">Cysticercosis Taenia solium </p><p id="p0176" num="0176">Cytomegalovirus infection Cytomegalovirus </p><p id="p0177" num="0177"> Dengue viruses (DEN-1, DEN-2,</p><p id="p0178" num="0178">Dengue fever </p><p id="p0179" num="0179"> DEN-3 and DEN- ) - Flaviviruses</p><p id="p0180" num="0180">Dientamoebiasis Dientamoeba fragilis </p><p id="p0181" num="0181"> Diphtheria Corynebacterium diphtheriae</p><p id="p0182" num="0182">Diphyllobothriasis Diphyl1obothriurn </p><p id="p0183" num="0183"> Dracunculiasis Dracunculus medinensis </p><p id="p0184" num="0184"> Ebola hemorrhagic fever Ebolavirus (EBOV) </p><p id="p0185" num="0185"> Echinococcosis Echinococcus genus </p><p id="p0186" num="0186"> Ehrlichiosis Ehrlichia genus </p><p id="p0187" num="0187"> Enterobiasis (Pinworm </p><p id="p0188" num="0188"> Enterobius vermicularis </p><p id="p0189" num="0189">infection) </p><p id="p0190" num="0190"> Enterococcus infection Enterococcus genus </p><p id="p0191" num="0191"> Enterovirus infection Enterovirus genus </p><p id="p0192" num="0192"> Epidemic typhus Rickettsia prowazekii </p><p id="p0193" num="0193"> Erythema infectiosum </p><p id="p0194" num="0194"> Parvovirus B19 </p><p id="p0195" num="0195">(Fifth disease) </p><p id="p0196" num="0196"> Exanthem subitum (Sixth Human herpesvirus 6 (HHV-6) and disease ) Human herpesvirus 7 (HHV-7) Fasciolopsiasis Fasciolopsis buski 
<!-- EPO <DP n="21"/>-->
DISEASE SOURCE OF DISEASE </p><p id="p0197" num="0197"> Fasciola hepatica and Fasciola</p><p id="p0198" num="0198">Fasciolosis </p><p id="p0199" num="0199"> gigantica </p><p id="p0200" num="0200"> Fatal familial insomnia </p><p id="p0201" num="0201"> FFI prion </p><p id="p0202" num="0202"> (FFI) </p><p id="p0203" num="0203"> Filariasis Filarioidea superfamily </p><p id="p0204" num="0204"> Food poisoning by </p><p id="p0205" num="0205"> Clostridium perfringens </p><p id="p0206" num="0206"> Clostridium perfringens </p><p id="p0207" num="0207"> Free-living amebic </p><p id="p0208" num="0208"> multiple </p><p id="p0209" num="0209">infection </p><p id="p0210" num="0210"> Fusobacterium infection Fusobacterium genus </p><p id="p0211" num="0211">Gas gangrene (Clostridial usually Clostridium perfringens; myonecrosis ) other Clostridium species </p><p id="p0212" num="0212">Geotrichosis Geotrichum candidum </p><p id="p0213" num="0213"> Gerstmann-Straussler- GSS prion </p><p id="p0214" num="0214">Scheinker syndrome (GSS) </p><p id="p0215" num="0215"> Giardiasis Giardia intestinalis </p><p id="p0216" num="0216"> Glanders Burkholderia mallei </p><p id="p0217" num="0217"> Gnathostoma spinigerum and </p><p id="p0218" num="0218"> Gnathostomiasis </p><p id="p0219" num="0219"> Gnathostoma hispidum </p><p id="p0220" num="0220"> Gonorrhea Neisseria gonorrhoeae </p><p id="p0221" num="0221"> Granuloma inguinale </p><p id="p0222" num="0222"> Klebsiella granulomatis </p><p id="p0223" num="0223">( Donovanosis ) </p><p id="p0224" num="0224"> Group A streptococcal </p><p id="p0225" num="0225"> Streptococcus pyogenes </p><p id="p0226" num="0226">infection </p><p id="p0227" num="0227"> Group B streptococcal </p><p id="p0228" num="0228"> Streptococcus agaiactiae </p><p id="p0229" num="0229">infection </p><p id="p0230" num="0230"> Haemophilus influenzae </p><p id="p0231" num="0231"> Haemophilus influenzae </p><p id="p0232" num="0232">infection </p><p id="p0233" num="0233"> Hand, foot and mouth Enteroviruses, mainly Coxsackie A disease (HFMD) virus and Enterovirus 71 (EV71)</p><p id="p0234" num="0234">Hantavirus Pulmonary </p><p id="p0235" num="0235"> Sin Nombre virus </p><p id="p0236" num="0236">Syndrome (HPS) </p><p id="p0237" num="0237"> Helicobacter pylori </p><p id="p0238" num="0238"> Helicobacter pylori </p><p id="p0239" num="0239">infection </p><p id="p0240" num="0240"> Hemolytic-uremic syndrome Escherichia coli 0157 :H7, 0111 (HUS) and O104:H4 </p><p id="p0241" num="0241"> Hemorrhagic fever with </p><p id="p0242" num="0242"> Bunyaviridae family </p><p id="p0243" num="0243">renal syndrome (HFRS) </p><p id="p0244" num="0244"> Hepatitis A Hepatitis A Virus </p><p id="p0245" num="0245"> Hepatitis B Hepatitis B Virus </p><p id="p0246" num="0246"> Hepatitis C Hepatitis C Virus </p><p id="p0247" num="0247"> Hepatitis D Hepatitis D Virus </p><p id="p0248" num="0248"> Hepatitis E Hepatitis E Virus 
<!-- EPO <DP n="22"/>-->
DISEASE SOURCE OF DISEASE </p><p id="p0249" num="0249"> Herpes simplex virus 1 and 2</p><p id="p0250" num="0250">Herpes simplex </p><p id="p0251" num="0251"> (HSV-1 and HSV-2) </p><p id="p0252" num="0252">Histoplasmosis Histoplasma capsulatum </p><p id="p0253" num="0253"> Ancylostoma duodenale and Necator Hookworm infection </p><p id="p0254" num="0254"> americanus </p><p id="p0255" num="0255"> Human bocavirus infection Human bocavirus (HBoV) </p><p id="p0256" num="0256"> Human ewingii </p><p id="p0257" num="0257"> Ehrlichia ewingii </p><p id="p0258" num="0258">ehrlichiosis </p><p id="p0259" num="0259"> Human granulocytic </p><p id="p0260" num="0260"> Anaplasma phagocytophilum anaplasmosis (HGA) </p><p id="p0261" num="0261"> Human metapneumovirus </p><p id="p0262" num="0262"> Human metapneumovirus (hMPV) infection </p><p id="p0263" num="0263"> Human monocytic </p><p id="p0264" num="0264"> Ehrlichia chaffeensis </p><p id="p0265" num="0265">ehrlichiosis </p><p id="p0266" num="0266"> Human papillomavirus </p><p id="p0267" num="0267"> Human papillomavirus (HPV) </p><p id="p0268" num="0268"> (HPV) infection </p><p id="p0269" num="0269"> Human parainfluenza virus Human parainfluenza viruses infection (HPIV) </p><p id="p0270" num="0270"> Hymenolepis nana and Hymenolepis</p><p id="p0271" num="0271">Hymenolepiasis </p><p id="p0272" num="0272"> diminuta </p><p id="p0273" num="0273"> Epstein-Barr Virus </p><p id="p0274" num="0274">Infectious Mononucleosis Epstein-Barr Virus (EBV) </p><p id="p0275" num="0275"> (Mono) </p><p id="p0276" num="0276"> Influenza (flu) Orthomyxoviridae family </p><p id="p0277" num="0277">Isosporiasis Isospora belli </p><p id="p0278" num="0278"> unknown; evidence supports that</p><p id="p0279" num="0279">Kawasaki disease </p><p id="p0280" num="0280"> it is infectious </p><p id="p0281" num="0281"> Keratitis multiple </p><p id="p0282" num="0282"> Kingella kingae infection Kingella kingae </p><p id="p0283" num="0283">Kuru Kuru prion </p><p id="p0284" num="0284"> Lassa fever Lassa virus </p><p id="p0285" num="0285"> Legionellosis </p><p id="p0286" num="0286"> Legionella pneumophila </p><p id="p0287" num="0287">(Legionnaires' disease) </p><p id="p0288" num="0288"> Legionellosis (Pontiac </p><p id="p0289" num="0289"> Legionella pneumophila </p><p id="p0290" num="0290">fever) </p><p id="p0291" num="0291"> Leishmaniasis Leishmania genus </p><p id="p0292" num="0292"> Mycobacterium leprae and </p><p id="p0293" num="0293"> Leprosy </p><p id="p0294" num="0294"> Mycobacterium lepromatosis </p><p id="p0295" num="0295"> Leptospirosis Leptospira genus </p><p id="p0296" num="0296"> Listeriosis Listeria monocytogenes </p><p id="p0297" num="0297"> Lyme disease (Lyme usually Borrelia burgdorferi and borreliosis ) other Borrelia species </p><p id="p0298" num="0298"> Lymphatic filariasis Wuchereria bancrofti and Brugia 
<!-- EPO <DP n="23"/>-->
DISEASE SOURCE OF DISEASE </p><p id="p0299" num="0299"> (Elephantiasis ) malayi </p><p id="p0300" num="0300"> Lymphocytic Lymphocytic choriomeningitis choriomeningitis virus (LCMV) </p><p id="p0301" num="0301"> Malaria Plasmodium genus </p><p id="p0302" num="0302"> Marburg hemorrhagic fever </p><p id="p0303" num="0303"> Marburg virus </p><p id="p0304" num="0304"> (MHF) </p><p id="p0305" num="0305"> Measles Measles virus </p><p id="p0306" num="0306"> Melioidosis (Whitmore's </p><p id="p0307" num="0307"> Burkholderia pseudomallei disease ) </p><p id="p0308" num="0308"> Meningitis multiple </p><p id="p0309" num="0309"> Meningococcal disease Neisseria meningitidis </p><p id="p0310" num="0310"> Metagonimiasis usually Metagonimus yokagawai</p><p id="p0311" num="0311">Microsporidiosis Microsporidia phylum </p><p id="p0312" num="0312"> Molluscum contagiosum </p><p id="p0313" num="0313"> Molluscum contagiosum virus (MCV) (MC) </p><p id="p0314" num="0314"> Mumps Mumps virus </p><p id="p0315" num="0315"> Murine typhus (Endemic </p><p id="p0316" num="0316"> Rickettsia typhi </p><p id="p0317" num="0317">typhus ) </p><p id="p0318" num="0318"> Mycoplasma pneumonia Mycoplasma pneumoniae </p><p id="p0319" num="0319"> numerous species of bacteria</p><p id="p0320" num="0320">Mycetoma (Actinomycetoma) and fungi </p><p id="p0321" num="0321"> (Eumycetoma) </p><p id="p0322" num="0322"> Myiasis parasitic dipterous fly larvae most commonly Chlamydia </p><p id="p0323" num="0323"> Neonatal conjunctivitis </p><p id="p0324" num="0324"> trachomatis and Neisseria </p><p id="p0325" num="0325">(Ophthalmia neonatorum) </p><p id="p0326" num="0326"> gonorrhoeae </p><p id="p0327" num="0327"> (New) Variant </p><p id="p0328" num="0328">Creutzfeldt-Jakob disease vCJD prion </p><p id="p0329" num="0329">(vCJD, nvCJD) </p><p id="p0330" num="0330"> usually Nocardia asteroides and</p><p id="p0331" num="0331">Nocardiosis </p><p id="p0332" num="0332"> other Nocardia species </p><p id="p0333" num="0333"> Onchocerciasis (River </p><p id="p0334" num="0334"> Onchocerca volvulus </p><p id="p0335" num="0335">blindness ) </p><p id="p0336" num="0336"> Paracoccidioidomycosis </p><p id="p0337" num="0337">(South American Paracoccidioides brasiliensis blastomycosis ) </p><p id="p0338" num="0338"> usually Paragonimus westermani</p><p id="p0339" num="0339">Paragonimiasis </p><p id="p0340" num="0340"> and other Paragonimus species</p><p id="p0341" num="0341">Pasteurellosis Pasteurella genus </p><p id="p0342" num="0342"> Pediculosis capitis (Head </p><p id="p0343" num="0343"> Pediculus humanus capitis lice ) </p><p id="p0344" num="0344"> Pediculosis corporis </p><p id="p0345" num="0345"> Pediculus humanus corporis </p><p id="p0346" num="0346">(Body lice) 
<!-- EPO <DP n="24"/>-->
 DISEASE SOURCE OF DISEASE </p><p id="p0347" num="0347"> Pediculosis pubis (Pubic </p><p id="p0348" num="0348"> Phthirus pubis </p><p id="p0349" num="0349">lice, Crab lice) </p><p id="p0350" num="0350"> Pelvic inflammatory </p><p id="p0351" num="0351"> multiple </p><p id="p0352" num="0352">disease (PID) </p><p id="p0353" num="0353"> Pertussis (Whooping </p><p id="p0354" num="0354"> Bordetella pertussis </p><p id="p0355" num="0355">cough) </p><p id="p0356" num="0356"> Plague Yersinia pestis </p><p id="p0357" num="0357"> Pneumococcal infection Streptococcus pneumoniae </p><p id="p0358" num="0358"> Pneumocystis pneumonia </p><p id="p0359" num="0359"> Pneumocystis jirovecii </p><p id="p0360" num="0360">(PCP) </p><p id="p0361" num="0361"> Pneumonia multiple </p><p id="p0362" num="0362">Poliomyelitis Poliovirus </p><p id="p0363" num="0363">Prevotella infection Prevotella genus </p><p id="p0364" num="0364">Primary amoebic </p><p id="p0365" num="0365"> usually Naegleria fowleri meningoencephalitis (PAM) </p><p id="p0366" num="0366"> Progressive multifocal </p><p id="p0367" num="0367"> JC virus </p><p id="p0368" num="0368">leukoencephalopathy </p><p id="p0369" num="0369"> Psittacosis Chlamydophila psittaci </p><p id="p0370" num="0370"> Q fever Coxiella burnetii </p><p id="p0371" num="0371"> Rabies Rabies virus </p><p id="p0372" num="0372"> Streptobacillus moniliformis and</p><p id="p0373" num="0373">Rat-bite fever </p><p id="p0374" num="0374"> Spirillum minus </p><p id="p0375" num="0375"> Respiratory syncytial </p><p id="p0376" num="0376"> Respiratory syncytial virus (RSV) virus infection </p><p id="p0377" num="0377"> Rhinosporidiosis Rhinosporidium seeberi </p><p id="p0378" num="0378"> Rhinovirus infection Rhinovirus </p><p id="p0379" num="0379"> Rickettsial infection Rickettsia genus </p><p id="p0380" num="0380"> Rickettsialpox Rickettsia akari </p><p id="p0381" num="0381"> Rift Valley fever (RVF) Rift Valley fever virus </p><p id="p0382" num="0382"> Rocky mountain spotted </p><p id="p0383" num="0383"> Rickettsia rickettsii </p><p id="p0384" num="0384">fever (RMSF) </p><p id="p0385" num="0385"> Rotavirus infection Rotavirus </p><p id="p0386" num="0386"> Rubella Rubella virus </p><p id="p0387" num="0387"> Salmonellosis Salmonella genus </p><p id="p0388" num="0388"> SARS (Severe Acute </p><p id="p0389" num="0389"> SARS coronavirus </p><p id="p0390" num="0390">Respiratory Syndrome) </p><p id="p0391" num="0391"> Scabies Sarcoptes scabiei </p><p id="p0392" num="0392"> Schistosomiasis Schistosoma genus </p><p id="p0393" num="0393">Sepsis multiple </p><p id="p0394" num="0394"> Shigellosis (Bacillary </p><p id="p0395" num="0395"> Shigella genus </p><p id="p0396" num="0396">dysentery) </p><p id="p0397" num="0397"> Shingles (Herpes zoster) Varicella zoster virus (VZV) 
<!-- EPO <DP n="25"/>-->
 DISEASE SOURCE OF DISEASE </p><p id="p0398" num="0398"> Smallpox (Variola) Variola major or Variola minor</p><p id="p0399" num="0399">Sporotrichosis Sporothrix schenckii </p><p id="p0400" num="0400"> Staphylococcal food </p><p id="p0401" num="0401"> Staphylococcus genus </p><p id="p0402" num="0402">poisoning </p><p id="p0403" num="0403"> Staphylococcal infection Staphylococcus genus </p><p id="p0404" num="0404"> Strongyloidiasis Strongyloides stercoralis </p><p id="p0405" num="0405"> Syphilis Treponema pallidum </p><p id="p0406" num="0406"> Taeniasis Taenia genus </p><p id="p0407" num="0407"> Tetanus (Lockjaw) Clostridium tetani </p><p id="p0408" num="0408"> Tinea barbae (Barber's </p><p id="p0409" num="0409"> usually Trichophyton genus itch) </p><p id="p0410" num="0410"> Tinea capitis (Ringworm </p><p id="p0411" num="0411"> usually Trichophyton tonsurans of the Scalp) </p><p id="p0412" num="0412"> Tinea corporis (Ringworm </p><p id="p0413" num="0413"> usually Trichophyton genus of the Body) </p><p id="p0414" num="0414"> usually Epidermophyton floccosum,</p><p id="p0415" num="0415">Tinea cruris (Jock itch) Trichophyton rubrum, and </p><p id="p0416" num="0416"> Trichophyton mentagrophytes</p><p id="p0417" num="0417">Tinea manuum (Ringworm of </p><p id="p0418" num="0418"> Trichophyton rubrum </p><p id="p0419" num="0419">the Hand) </p><p id="p0420" num="0420"> Tinea nigra usually Hortaea werneckii </p><p id="p0421" num="0421"> Tinea pedis (Athlete' s </p><p id="p0422" num="0422"> usually Trichophyton genus foot) </p><p id="p0423" num="0423"> Tinea unguium </p><p id="p0424" num="0424"> usually Trichophyton genus </p><p id="p0425" num="0425"> (Onychomycosis ) </p><p id="p0426" num="0426"> Tinea versicolor </p><p id="p0427" num="0427"> Malassezia genus </p><p id="p0428" num="0428"> (Pityriasis versicolor) </p><p id="p0429" num="0429"> Toxocariasis (Ocular </p><p id="p0430" num="0430"> Toxocara canis or Toxocara cati Larva Migrans (OLM) ) </p><p id="p0431" num="0431"> Toxocariasis (Visceral </p><p id="p0432" num="0432"> Toxocara canis or Toxocara cati Larva Migrans (VLM) ) </p><p id="p0433" num="0433"> Toxoplasmosis Toxoplasma gondii </p><p id="p0434" num="0434"> Trichinellosis Trichinella spiralis </p><p id="p0435" num="0435"> Trichomoniasis Trichomonas vaginalis </p><p id="p0436" num="0436"> Trichuriasis (Whipworm </p><p id="p0437" num="0437"> Trichuris trichiura </p><p id="p0438" num="0438">infection) </p><p id="p0439" num="0439"> usually Mycobacterium </p><p id="p0440" num="0440"> Tuberculosis </p><p id="p0441" num="0441"> tuberculosis </p><p id="p0442" num="0442"> Tularemia Francisella tularensis </p><p id="p0443" num="0443"> Ureaplasma urealyticum </p><p id="p0444" num="0444"> Ureaplasma urealyticum </p><p id="p0445" num="0445">infection </p><p id="p0446" num="0446"> Venezuelan equine Venezuelan equine encephalitis encephalitis virus 
<!-- EPO <DP n="26"/>-->
DISEASE SOURCE OF DISEASE </p><p id="p0447" num="0447"> Venezuelan hemorrhag </p><p id="p0448" num="0448"> Guanarito virus </p><p id="p0449" num="0449">fever </p><p id="p0450" num="0450"> Viral pneumonia multiple viruses </p><p id="p0451" num="0451"> West Nile Fever West Nile virus </p><p id="p0452" num="0452"> White piedra (Tinea </p><p id="p0453" num="0453"> Trichosporon beigelii </p><p id="p0454" num="0454">blanca) </p><p id="p0455" num="0455"> Yersinia </p><p id="p0456" num="0456">pseudotuberculosis Yersinia pseudotuberculosis infection </p><p id="p0457" num="0457"> Yersiniosis Yersinia enterocolitica </p><p id="p0458" num="0458"> Yellow fever Yellow fever virus </p><p id="p0459" num="0459"> Mucorales order (Mucormycosis]</p><p id="p0460" num="0460">Zygomycosis and Entomophthorales order </p><p id="p0461" num="0461"> (Entomophthoramycosis ) </p><p id="p0462" num="0462">TLR agonist B is selected from those listed in Table (also see Zuany-Amorim et al . Nature Reviews Drug Discove 2002 1: 797-807) . </p><p id="p0463" num="0463">Table 2 : Toll-like Receptors </p><p id="p0464" num="0464"> TLR-family member Exogenous Ligands </p><p id="p0465" num="0465"> TLR-1 (can Mycobacterial lipoprotein, triacylated associate with lipopeptides </p><p id="p0466" num="0466">TLR-2) </p><p id="p0467" num="0467"> TLR-2 (can LPS, yeast-particle zymosan, </p><p id="p0468" num="0468">associate with peptidoglycan (bacteria) , lipoproteins TLR-1 or TLR- 6) (bacteria and mycoplasmas) , GPI anchor from Trypanosoma cruzi </p><p id="p0469" num="0469"> TLR-3 Poly(I:C) (viral dsR A) </p><p id="p0470" num="0470"> TLR-4 LPS, respiratory syncytial virus</p><p id="p0471" num="0471">TLR-5 Flagellin </p><p id="p0472" num="0472"> TLR- 6 (can Mycoplasma lipoproteins, lipoteichoic associate with acid, peptidoglycan (bacteria) </p><p id="p0473" num="0473">TLR-2) </p><p id="p0474" num="0474"> TLR-7 Unknown; synthetic compounds such as resiquimod or imiquimod, activate the receptor </p><p id="p0475" num="0475"> TLR-8 Unknown; synthetic compounds such as resiquimod or imiquimod, activate the receptor </p><p id="p0476" num="0476"> TLR-9 CpG DNA </p><p id="p0477" num="0477"> TLR-10 Unknown 
<!-- EPO <DP n="27"/>-->
Manufacture of Antigen A and TLR Agonist B particles </p><p id="p0478" num="0478"> Stock cationic particles are prepared by a melt- emulsification-chill process as follows. Yellow Carnauba wax (YC) , 10 grams, comprised of 40% aliphatic esters, 21% diesters of 4-hydroxycinnamic acid, 13% ω-hydroxycarboxylic acids and 12% fatty acid alcohols is melted in a 250 mL glass beaker at 90°C. In a second 250 mL glass beaker, 90 mL of 1% cationic surfactant solution (either cetyl triammonium bromide (CTAB) or cetylpyridinium bromide (CPB) ) is heated to 90 °C. The hot aqueous surfactant solution is added to the molten YC wax with tip sonication for 3 minutes to form an emulsion. The emulsion is then rapidly cooled using an ice- bath with an overhead stirrer. A 1% w/w dispersion is prepared by diluting this emulsion stock with water. </p><p id="p0479" num="0479"> The selected TLR Agonist B solution is prepared by dilution with water to achieve either 1 mg/mL or 10 mg/mL working solution. </p><p id="p0480" num="0480"> The Antigen A solution is prepared in a 10% DMSO/water mixture and used immediately to avoid antigen degradation. </p><p id="p0481" num="0481"> The required volumes of the TLR Agonist B solution and the Antigen A solution in order to achieve the desired final concentration are pipetted into a sterile 2 mL plastic vial, VIAL 1, and mixed by inversion. The required volume of 1% w/w cationic particle dispersion and the required volume of water consistent with the desired final concentration is pipetted into a separate sterile 2 mL plastic vial, VIAL 2, and mixed by inversion. Each final formulation is prepared by transferring by Eppendorf pipette, with drop-wise addition, all the solutions in VIAL 1 to VIAL 2. The final mixture in VIAL 2 is then inverted three times to yield the final Antigen A and TLR Agonist B Particle formulation ready for use. 
</p></description><claims mxw-id="PCLM70076547" ref-ucid="WO-2014130921-A1" lang="EN" load-source="patent-office"><claim id="clm-0001" num="0001"><!-- EPO <DP n="28"/>--><claim-text>What is Claimed is: </claim-text><claim-text> 1. A composition comprising one or more TLR agonists, one or more antigens and a first plurality of particles to which the one or more TLR agonists and one or more antigens are attached, said one or more antigens and said one or more TLR agonists being at a ratio which increases immunogenicity to the one or more antigens and/or decreases reactogenicity to the one or more TLR agonists . 2. The composition of claim 1 wherein the one or more</claim-text><claim-text>TLR agonists and one or more antigens are both attached to the first plurality of particles. </claim-text><claim-text>3. The composition of claim 1 further comprising a second plurality of particles wherein the one or more TLR agonists are attached to the first plurality of particles and the one or more antigens are attached to the second plurality of particles. 4. The composition of any of claims 1 through 3 wherein the particles are comprised of a lipid. </claim-text><claim-text>5. The composition of claim 4 wherein the lipid is selected from the group consisting of Dynasanll8 / PEG35- castor oil blend, natural Carnauba wax, synthetic carnauba wax, Bees wax, a self-emulsifying wax, polyethylene wax, behenyl alcohol and oleic acid/compritol . </claim-text><claim-text>6. The composition of claim 4 wherein the lipid is carnauba wa . </claim-text><claim-text>7. The composition of claim 6 wherein the carnauba wax comprises aliphatic esters, diesters of 4- 
<!-- EPO <DP n="29"/>-->
hydroxycinnamic acid ω-hydroxycarboxylic acids and fatty acid alcohols . </claim-text><claim-text>8. The composition of any of claims 1 through 7 wherein the ratio of the TLR agonist to antigen is less than about 1:5 on a weight to weight basis. </claim-text><claim-text>9. The composition of any of claims 1 through 7 wherein the ratio of the TLR agonist to antigen is less than about 1:20 on a molecule to molecule basis. </claim-text><claim-text>10. The composition of any of claims 1 through 9 further comprising a surfactant. </claim-text><claim-text>11. The composition of claim 10 wherein the surfactant is selected from the group consisting of cetyl triammonium bromide (CTAB) , N- [ 1- (2 , 3-Dioleoyloxy) ] -N, N, N- trimethylammonium propane methylsulfate DOT7AP, </claim-text><claim-text>cetylpyridinium bromide (CPB) , Tween 20, Tween 80 </claim-text><claim-text>(polyoxyethylene sorbitan monoloaurate) , Brij 70, sodium stearate, sodium myristate, sodium dodecyl sulfate, dioctyl sodium sulfosuccinate and combinations thereof. </claim-text><claim-text>12. The composition of claim 10 wherein the surfactant is cetyl trimethylammonium bromide. </claim-text><claim-text>13. The composition of claim 10 wherein the surfactant is cetylpyridinium bromide. </claim-text><claim-text>1 . The composition of any of claims 1 through 13 further comprising a targeting moiety. 
<!-- EPO <DP n="30"/>-->
</claim-text><claim-text>15. The composition of any of claims 1 through 14 wherein the TLR agonist and antigens are attached to the particle through electrostatic interactions . </claim-text><claim-text>16. The composition of any of claims 1 through 14 wherein the TLR agonist and antigens are attached to the particle through hydrophilic interactions . </claim-text><claim-text>17. The composition of any of claims 1 through 14 wherein the TLR agonist and antigens are attached to the particle through non-covalent interactions. </claim-text><claim-text>18. The composition of any of claims 1 through 17 wherein the TLR agonist has an affinity for and stimulates physiologic activity of either TLRl , TLR2, TLR3 , TLR4, TLR6, TLR7 , TLR8 , TLR9, TLR10 , TLRll or TLR12. </claim-text><claim-text>19. The composition of any of claims 1 through 17 wherein the TLR agonist has an affinity for and stimulated physiologic activity of TLR5. </claim-text><claim-text>20. A method of making the composition of claim 1 comprising : </claim-text><claim-text> (a) preparing a hot aqueous surfactant solution; </claim-text><claim-text> (b) adding the hot surfactant to a molten lipid to form a hot lipid/surfactant mixture; </claim-text><claim-text> (c) adding. the hot lipid/surfactant mixture to an aqueous phase to form a second mixture; </claim-text><claim-text> (d) sonicating the second mixture; </claim-text><claim-text> (e) cooling the second mixture; and </claim-text><claim-text> (f) adding one or more TLR agonists and one or more antigens to form a composition comprising particles to which 
<!-- EPO <DP n="31"/>-->
one or more TLR agonists and one or more antigens is attached . </claim-text><claim-text>21. A method of making the composition of claim 3 comprising: </claim-text><claim-text> (a) preparing a hot aqueous surfactant solution; </claim-text><claim-text> (b) adding the hot surfactant to a molten lipid to form a hot lipid/surfactant mixture; </claim-text><claim-text> (c) adding the hot lipid/surfactant mixture to an aqueous phase to form a second mixture; </claim-text><claim-text> (d) sonicating the second mixture; </claim-text><claim-text> (e) cooling the second mixture; </claim-text><claim-text> (f) adding one or more TLR agonists to form a </claim-text><claim-text>composition comprising particles to which one or more TLR agonists is attached; </claim-text><claim-text> (g) repeating steps (a) through (e) and adding to the resulting mixture one or more antigens to form a composition comprising particles to which one or more antigens is attached; and </claim-text><claim-text> (h) mixing together the particles of step (f) and the particles of step (g) . </claim-text><claim-text>22. The method of claim 20 or 21 wherein the </claim-text><claim-text>surfactant is cetyl triammonium bromide. </claim-text><claim-text>23. The method of claim 20 or 21 wherein the </claim-text><claim-text>surfactant is cetylpyridinium bromide . </claim-text><claim-text>24. The composition of any of claims 1 through 19 wherein the antigen is at least 10% more immunogenic than the antigen alone in solution. 
<!-- EPO <DP n="32"/>-->
</claim-text><claim-text>25. The composition of any of claims 1 through 19 wherein the antigen is at least 10% more immunogenic than the antigen fused to the TLR agonist. 26. The composition of any of claims 1 through 19 wherein the TLR agonist is at least 10% less reactogenic than the TLR agonist alone in solution. </claim-text><claim-text>27. The composition of any of claims 1 through 19 wherein the TLR agonist is at least 10% less reactogenic than the antigen fused to the TLR agonist. </claim-text><claim-text>28. A method for inducing an immune response in a human, said method comprising administering the composition of any of claims 1 through 19. </claim-text><claim-text>29. A method for increasing antibody response to a poorly antigenic antigen in an animal, said method </claim-text><claim-text>comprising administering to the animal the composition of any of claims 1 through 19. 
</claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
